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AT A GLANCE COMMENTARY 
Scientific knowledge on the subject: Long-term and prophylactic antibiotics including 
macrolides are being increasingly used in the management of frequently exacerbating patients 
with chronic respiratory disease including severe asthma, COPD and bronchiectasis. The 
airway resistome, while recognised, is poorly characterised and its relationship to the host 
microbiome unknown. 
What this study adds to the field: We, for the first time, in the largest and deepest 
metagenomics assessment of the airway evaluate airway resistomes across chronic respiratory 
disease states, and, relate them to host microbiomes. We identify a ‘core’ airway resistome, 
harboured by the host microbiome, and, dominated by macrolide resistance genes but with high 
prevalence of -lactam, fluoroquinolone and tetracycline resistance. This ‘core’ resistome is 
independent of health status or antibiotic exposure and shares significant overlap with 
resistomes detected on paired patient inhaler devices where the latter represents a proxy for the 
host microbiome. Metagenomic analysis of the airway reveals a core macrolide resistome with 
implications for potential macrolide antibiotic resistance in the management of respiratory 
disease.
Online data supplement statement: This article has an online data supplement, which is 
accessible from this issue's table of contents online at www.atsjournals.org
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ABSTRACT
Rationale: Long-term antibiotic use for managing chronic respiratory disease is increasing 
however the role of the airway resistome and its relationship to host microbiomes remains 
unknown 
Objective: To evaluate airway resistomes, and, relate them to host and environmental 
microbiomes using ultra-deep metagenomic shotgun sequencing Methods: Airway specimens 
from n=85 individuals with and without chronic respiratory disease (severe asthma, COPD and 
bronchiectasis) were subjected to metagenomic sequencing to an average depth exceeding 
twenty million reads. Respiratory and device-associated microbiomes were evaluated based on 
taxonomical classification and functional annotation including the Comprehensive Antibiotic 
Resistance Database (CARD) to determine airway resistomes. Co-occurrence networks of 
gene-microbe association were constructed to determine potential microbial sources of the 
airway resistome. Paired patient-inhaler metagenomes were compared (n=31) to assess for the 
presence of airway-environment overlap in microbiomes and/or resistomes. 
Results: Airway metagenomes exhibit taxonomic and metabolic diversity and distinct 
antimicrobial resistance patterns. A ‘core’ airway resistome dominated by macrolide but with 
high prevalence of -lactam, fluoroquinolone and tetracycline resistance genes exist, and, is 
independent of disease status or antibiotic exposure. Streptococcus and Actinomyces are key 
potential microbial reservoirs of macrolide resistance including the ermX, ermF and msrD 
genes. Significant patient-inhaler overlap in airway microbiomes and their resistomes is 
identified where the latter may be a proxy for airway microbiome assessment in chronic 
respiratory disease. 
Conclusion: Metagenomic analysis of the airway reveals a core macrolide resistome harboured 
by the host microbiome.
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INTRODUCTION
The development, progression and associated phenotypes of chronic airways disease has been 
associated with perturbation of the airway microbiome. Such airway dysbiosis is often 
characterised by predominance of pathogenic bacteria such as Haemophilus, Streptococcus 
and/or Pseudomonas which co-exist with a gamut of other taxa forming the airway 
‘pathobiome’ (1, 2). Patients with airways disease and frequent exacerbations are therefore 
prescribed long-term antibiotic regimes aiming to reduce bacterial burden, inflammation and 
improve clinical symptoms with variable results (3-5). The selective pressure resulting from 
such an approach however promotes antimicrobial resistance, a key global concern and serious 
threat to public health (5).
The impact of antimicrobial exposure on lung microbiome architecture, and, mechanisms 
promoting antimicrobial resistance remain an intense area of clinical and research interest. In 
addition, the broader implications of antibiotic exposure on the resident airway resistome, 
beyond that related to the target bacterial pathogen alone, has lacked study. This is important 
as interspecies interactions are plentiful in the airway, and, the emergence of resistance in non-
pathogenic organisms are key factors potentially influencing therapeutic outcomes (6). 
Moreover, the environment remains a vast, mobilizable reservoir of resistance determinants 
with great potential to seed the airway resistome but remains inadequately characterised in the 
setting of chronic respiratory disease states (7). 
As next generation sequencing becomes cheaper, the era of clinical metagenomics represents 
an emerging and robust molecular tool allowing characterisation of airway microbiomes in 
tandem to assessment of their functional properties for use in diagnosis, treatment and/or 
patient risk stratification (8, 9). Work performed in Cystic Fibrosis (CF) reveals the cumulative 
effect of antibiotic exposure on the airway microbiome and recent data in chronic obstructive 
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pulmonary disease (COPD) confirms the airway as an important reservoir for antimicrobial 
resistance genes, however, no work has been performed using metagenomics and no dedicated 
studies including severe asthma or bronchiectasis (10, 11). Unlike targeted amplicon 
sequencing approaches (e.g. 16S rRNA) metagenomic shotgun sequencing remains less 
susceptible to polymerase chain reaction (PCR) amplification bias, is not influenced by copy 
number variation and, critically, provides scope to probe the functional aspects of the 
microbiome including its resistome (9, 12, 13).  
Here, we report the largest application of deep metagenomic shotgun sequencing to airway 
samples across a range of chronic respiratory disease states (severe asthma, COPD and 
bronchiectasis) and include non-diseased (healthy) individuals to characterise resident airway 
resistomes. We provide taxonomic and functional insight to airway-based resident antibiotic 
resistance in health and disease, and, further assess patient inhaler devices as a potential 
environmental reservoir of resistance. Some of the results of these studies have been previously 
reported in the form of an abstract (14).
METHODS
Study Population(s)
Patients with respiratory disease were prospectively recruited during routine attendance at 
respiratory outpatient clinics at two tertiary hospital sites in Singapore (Table 1): Singapore 
General Hospital (SGH) and Tan Tock Seng Hospital (TTSH). Non-diseased (healthy) 
individuals were recruited through an established voluntary exercise program at Nanyang 
Technological University (NTU), Singapore. Severe asthma patients were graded as being at 
least step four of the Global Initiative for Asthma (GINA) guideline treatment ladder and met 
current criteria for severe asthma. COPD was defined according to the global initiative for 
chronic obstructive lung disease (GOLD) criteria and bronchiectasis (Non-CF) was defined by 
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radiological confirmation of bronchiectasis by either dynamic Computed tomography (CT) or 
High-resolution computed tomography (HRCT) thorax in accordance with British Thoracic 
Society guidelines along with the absence of any other major concurrent chronic respiratory 
disease state (15-18). Non-diseased (healthy) individuals had no active or past history of any 
respiratory or other medical disease and normal spirometry measured in accordance with 
ERS/ATS criteria. Non-diseased individuals were free from any exposure to inhaled 
medications or antibiotic use in the preceding 12-month period. Demographics and associated 
clinical data were collated including age, sex, ethnicity, body mass index (BMI), lung function 
(FEV1 % predicted), smoking status and antibiotic use in the preceding six-month period. In 
addition, the number of exacerbations in the year preceding study recruitment was recorded for 
all patients with respiratory disease (severe asthma, COPD and bronchiectasis) and these 
patient groups had their respective disease severity/control scores recorded respectively by the 
Asthma Control Test (ACT), Global Initiative for Obstructive Lung Disease (GOLD) score 
and Bronchiectasis Severity Index (BSI) (15, 19, 20). 
Whole-genome shotgun sequencing of clinical and environmental samples
Representative, spontaneously expectorated sputum samples were obtained from all 
participants through directed coughing using the Huff cough manoeuvre. An independent and 
prospective cohort of patients with severe asthma, COPD or bronchiectasis (as defined above) 
using regular inhaled bronchodilator and/or corticosteroid therapy were recruited and the 
inhaler used most frequently sampled (Supplementary Table E1). Patients had documented 
self-reported inhaler adherence over the preceding six-month period and demonstrated 
objective evidence of stable and/or improved pulmonary function on spirometry. Paired airway 
specimen (sputum) and an inhaler swab was obtained and subjected to metagenomic analysis. 
DNA was extracted from airway and environmental samples according to previously described 
clinical and environmental sampling methods (21, 22). DNA was used in the preparation of 
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metagenomic shotgun sequencing libraries as described (23). Resultant sequence data was 
processed and quality trimmed before subjecting it to secondary analysis to derive taxonomic 
and functional genomic profiles including analysis with specific reference to the 
Comprehensive Antimicrobial Resistance Database (CARD) to assess the metagenomic 
resistome in all patient and environmental specimens (24). 
Full details on DNA extraction, metagenomic sequencing, functional and taxonomic 
assignment of metagenomic sequence reads, data analysis, visualization, statistical analysis and 
details on ethical approvals are provided in the supplementary material.
RESULTS 
The airway metagenome exhibits functional metabolic dysbiosis and antibiotic resistance: 
Functional classification of microbial gene content based on read assignment to functional 
categories illustrates variability in patients with COPD and bronchiectasis in contrast to 
relatively comparable profiles in healthy individuals and severe asthma patients (Figure 1A). 
A dysbiotic shift in the abundance of carbohydrate and amino acid related pathways toward 
lipid-associated pathways is evident in COPD and bronchiectasis with the latter exhibiting 
greatest change (Figure 1A). Classification of metagenomic data with reference to the KEGG 
functional database further reveals alteration in genes associated with antibiotic-associated 
pathways including degradation, detoxification and anti-microbial resistance (25). While drug-
related and xenobiotic metabolism is increased in COPD and bronchiectasis, genes involved in 
streptomycin, butirosin, neomycin and  -lactamase biosynthesis are abundant in severe 
asthma and healthy individuals (Figure 1A). To probe specifically for the composition of 
antibiotic resistance genes within the airway metagenome, reads were classified with reference 
to the CARD database – a dataset of curated antibiotic-resistance genes (24). Derived antibiotic 
resistance gene profiles exhibit variability across the healthy and diseased states with 
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contrasting abundances of aminoglycoside, bicyclomycin, diaminopyrimidine, multi-drug, 
peptide, phenicol, sulphonamides, sulfones and triclosan resistance genes (Figure 1B). 
Critically, recent antibiotic exposure (selective pressure) did not translate to a detectable higher 
relative abundance of anti-microbial resistance (AMR) and importantly, AMR profiles of 
healthy individuals and patients unexposed to antibiotics in the preceding six month period  
exhibit a significant presence of AMR suggesting the presence of a core airway resistome 
(Figure 1C, Table 2). 
The core airway resistome: Variable assemblages of antibiotic resistance genes are identified 
across individual disease cohorts including healthy individuals. Patients with COPD and 
bronchiectasis have the greatest repertoire of antibiotic resistance determinants, although this 
was potentially biased by the greater number of patients in these groups (Figure 2A). Patients 
with COPD harboured the highest diversity of resistance genes (n=92; 85% shared with other 
cohorts) distinguished by the presence of specific -lactam, fluoroquinolone, macrolide, multi-
drug, phenicol and tetracycline resistance determinants. While healthy individuals and severe 
asthmatics had a slightly lower number of cumulative AMR sequences, analysis revealed a 
strikingly consistent subset of 18 AMR genes common to all cohorts (including healthy) 
representing a ‘core resistome’ (Figure 2B, Table 2). Importantly, this ‘core resistome’ was 
predominated by AMR genes from the -lactam, fluoroquinolone, macrolide and tetracycline 
classes (Figure 1B, 2B and 2C, Table 2) and detectable in every individual recruited into our 
study irrespective of health or disease status and did not differ by type of chronic respiratory 
disease. In aggregate, genes encompassing a ‘core macrolide resistome’ were most abundant 
and included msrD (mel), ermB, ermX and ermF accompanied by genes encoding tetracycline 
(tetW, tetA(46), tetB (46)), -lactam (cfxA2), and fluoroquinolone (pmrA) resistance (Figure 
2C, Table 2).
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The microbial ecology of sputum samples across respiratory disease states: Deep 
sequencing of sputum revealed a microbiome profile dominated by bacteria, with fungi and 
viruses accounting for <0.01% and <0.25% average relative abundance respectively 
(Supplementary Figure E1). Dysbiosis of the respiratory microbiome was evident across 
chronic respiratory disease in line with established literature (Figure 3A) (26). Microbiome -
diversity between groups varied with healthy individuals exhibiting highest Shannon diversity 
compared to disease (Supplementary Figure E3A). Simpson diversity was comparable across 
cohorts while patients with severe asthma and bronchiectasis exhibited reduced Chao1 
(Supplementary Figure E3B and E3C). Among the respiratory disease cohorts, microbiome 
profiles were distinguished by Actinobacteria (Rothia spp.) and proteobacteria (Pseudomonas 
and Haemophilus spp.) which exhibited increased abundance in diseased cohorts with 
corresponding reductions in Prevotella spp., Treponema spp. Fusobacteria spp. and diverse 
firmicutes compared to healthy individuals based on linear discriminant analysis 
(Supplementary Figure E3D and E3E). Among diseased patients, the increased abundance of 
Rothia mucilaginosa and Pseudomonas aeruginosa were among the most striking species-level 
differences associated with disease status in our analysis (Figure 3A). Fungi were detected 
sporadically and at low abundance and microbiome -diversity reveals heterogeneity to be 
highest in bronchiectasis, followed by COPD (Figure 3B). Conversely, healthy and severe 
asthma have more evenly distributed and diverse bacterial species in their airways further 
supported by analysis of average centroid distances, which is greatest in COPD and 
bronchiectasis (Figure 3C). 
Gene-microbe co-occurrence in the core resistome: We next looked at correlation between 
microbial taxa and the ‘core’ resistome by constructing a co-occurrence network of microbes 
and their respective antibiotic resistance genes (Figure 4). This revealed significant 
relationships (including correlation) between resistance genes (Figure 4A) and airway 
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microbiota (Figure 4B) allowing inference of gene-microbe associations within an integrated 
holistic network. We focused on the ‘core’ macrolide resistome because it formed a key 
component of the ‘core’ resistome (Figure 2B and Figure 2C) and is an antibiotic class gaining 
widespread use across chronic respiratory disease states (17, 27, 28). The macrolide resistance 
gene ermX, represents a highly connected node associated with several microbial taxa (Figure 
4C). These predominantly consist of upper airway commensals containing only few overtly 
pathogenic species (Figure 4C). Network inference further identifies a lesser number of 
microbial associations with ermF (Figure 4D) and msrD (Figure 4E) respectively. Streptococci 
and Actinomyces were associated with ermX and ermB while the strongest association detected 
is between ermF and the gut microbe Bacteroidetes thetaiotaomicron. Associations between 
msrD and the gut pathogen Clostridioidies difficile and the largely unstudied Morococcus 
cerebrosus were also detected (Figure 4D-E).
Metagenomics identifies inhaler devices as potential sinks for antibiotic resistance : To 
assess for potential sites of resistance host-environment transfer, patient inhaler devices with 
respectively paired airway specimens were obtained in an independent prospectively recruited 
cohort of patients with chronic respiratory disease and subjected to metagenomics sequencing 
and analysis (Supplementary table E1). We identify significant overlap between the airway 
metagenome and that detectable on patient-paired inhaler devices with a significant number of 
microbial taxa found on both specimens (Figure 5A). This suggests that an inhaler swab, when 
subjected to metagenomics could represent a surrogate measure of a patient’s airway 
microbiome. The number of microbes observed on inhaler devices (n=207) exceeds that 
detected from the airways (n=116) suggestive of other potential environmental influences 
however, 80 overlapping microbial taxa were observable in paired airway-inhaler specimens 
with 36 and 127 microbial taxa found in airway and inhaler devices respectively, suggesting 
increased microbial diversity on inhaler devices including microbes of potential environmental 
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origin (Figure 5B). Among the 80 co-occurring microbial taxa, most (63 species and 78.8% of 
all co-occurring taxa) were detected at the individual level in specimens obtained from the 
same patient, illustrated for the most abundant taxa in Figure 5C. Similar analyses focused on 
antibiotic resistance genes reveals comparable metagenomic profiles from paired airway-
inhaler device specimens but with lower resistance gene abundance on inhaler devices (Figure 
5D). Here, multi-drug, macrolide and tetracycline antibiotic resistance determinants were most 
frequently observed, a finding consistent with our previously described ‘core’ resistome 
(Figure 5D). A slightly higher number of resistance determinants (n=98) were found associated 
to inhaler devices as compared to airway specimen (n=89), a finding consistent with the greater 
diversity of microbes seen on inhalers, while 53 resistance genes were overlapping between 
inhalers and sputum (Figure 5E). Among overlapping resistance genes between the airway-
inhaler device, 86.8% (46 resistance genes) co-occurred in paired airway-inhaler device 
specimens illustrated for the most abundant resistance genes in Figure 5F. A subset of 
identified resistance genes was associated with inhaler devices without detectable levels in the 
sputum of any patient or non-diseased control. These genes may reflect potential environmental 
sources of resistance gene diversity, 12 of which were independently observed on at least two 
inhaler devices (Supplementary Table E2). 
Co-occurrence analysis of gene-microbe associations in sputum and inhaler devices: We 
next sought to further assess microbial correlates of resistance among the subset of microbes 
(n = 63) and resistance genes (n = 46) with confirmed co-occurrence detected across the paired 
airway-inhaler devices (Figures 5C and 5F). Consistent with resistance gene abundance, the 
most highly correlated gene-microbe pairs included genes conferring resistance to macrolides 
(n=4), tetracyclines (n=4), -lactams (n=1) and fluoroquinolones (n=1). Several species exhibit 
significant correlation with co-occurring resistance genes and predominantly comprise of 
Firmicutes (Carnobacterium, Granulicatella, Prevotella and Streptococcus) and 
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Actinobacteria (Actinomyces, Corynebacterium and Rothia) (Figure 6A). Correlation analysis 
reveals significant association for all four macrolide genes (msrD, ermF, ermB and ermX) as 
well as fluoroquinolone (pmrA), tetracycline (tetA_46 and tetB_46) and -lactam (cfxA2) 
resistance determinants. The most highly correlated species associated with msrD was 
Carnobacterium maltaromanticum; a lactic acid bacterium frequently found in food products 
including fish, meat, and some dairy. Prevotella intermedia was most closely correlated with 
ermF while Actinomyces ICM47 was associated with ermF and ermX gene abundance. 
Streptococci associated with the presence of fluoroquinolone and tetracycline resistance 
determinants while Prevotella pallens was identifiable as the most likely microbial source of 
cfxA2 -lactamase based on maximal correlation coefficients and significance compared to 
other taxa. The abundance of these putative microbial resistance vehicles and their associated 
resistance genes are illustrated in Figure 6B. 
DISCUSSION
We describe the largest airway clinical metagenomics analyses performed to date linking the 
antimicrobial resistome to host microbiomes in chronic respiratory disease. Our work 
highlights the versatility and usefulness of metagenomics in assessing functional aspects of the 
human microbiome, including antibiotic resistance. The airway metagenome exhibits 
functional metabolic dysbiosis including increased antibiotic resistance, predominant in COPD 
and bronchiectasis. Variability exists in antibiotic-associated functional pathways in healthy 
and diseased airways, mirrored by a presence and high abundance of resistance genes. 
Critically, we uncover, even in a healthy state, the presence of a ‘core’ resistome; dominated 
by genes from common antibiotic classes including macrolides, β-lactams and fluroquinolones 
unrelated to antibiotic exposure. By assessing host microbiomes with increased robustness 
provided by metagenomics, we link the presence of specific bacterial taxa to the ‘core’ 
resistome and specifically genes conferring macrolide resistance. Analysis of paired patient-
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inhaler metagenomes illustrates significant overlap suggesting the latter as a surrogate for the 
host microbiome. Patient-inhaler overlap confirms our identified resistance gene-microbe 
associations as well as identifies resistance determinants unique to inhaler devices aligning 
with the concept of the wider environment as source of resistance determinants linked to 
microbial, and, therefore resistance transfer between environment and host. 
A key observation from this work is the high abundance of resistance genes within the 
Macrolide-Lincosamide-Streptogramin (MLS) axis which dominates the airway resistome. 
This is important given the widespread and increasing use of macrolides across a variety of 
clinical respiratory diseases (4, 29-31). Prior work illustrates that macrolide resistance is 
amongst the most prevalent in the wider environment, representing a rich source of resistance 
determinants with strong potential for horizontal transfer (32). Our detection of a ‘core’ airway 
resistome dominated by macrolide resistance is therefore of particular concern considering the 
selective pressure exerted by macrolides toward resistance in both the airway and wider 
environment (30, 33, 34). Recent work focused on environmental resistomes illustrates their 
distinct core and discriminatory elements (35). We, in similar fashion, detected core and 
discriminatory elements within the airway metagenome, where discriminant resistance genes 
had higher occurrence in diseased states (e.g multidrug resistance in COPD and bronchiectasis) 
which associated with their microbiomes. A core airway resistome is also evident comprising 
of genes from the macrolide, fluoroquinolone,  -lactam and tetracycline antibiotic classes. 
This core resistome demonstrates stability across all respiratory diseases including healthy 
individuals, and, therefore explains the detected relative microbiome stability during 
exacerbations despite antibiotic pressure (30, 36, 37). Our description of the ‘core’ airway 
resistome also provides a novel perspective on reasons why pathogens, expected to exhibit in-
vivo susceptibility to a particular antibiotic, are not necessarily eradicated by appropriate 
antimicrobial therapy (38).
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Predominance of macrolide resistance within the core resistome is of relevance in respiratory 
disease. Macrolide use is advocated in severe asthma, COPD and more recently bronchiectasis, 
particularly for patients demonstrating recurrent and persistent exacerbations (27, 28, 39). The 
‘core’ macrolide resistome includes msrD (mel), ermB, ermX and ermF genes which 
incorporates efflux (msrD) and rRNA methylases (erm),  mechanisms previously established 
in the human gut and sewage effluent (32, 34, 40). Of all macrolide resistance genes identified, 
ermX exhibits greatest abundance in respiratory disease, and, presents as a highly connected 
node in our co-occurrence analysis, its presence relating to several resident airway bacteria. 
Interestingly, ermF and mstD exhibit association with low abundance gut microbiota including 
Clostridiodes difficile and Bacteroides thetaiotaomicron which are reported to harbour these 
genes in association with mobile genetic elements (41, 42). This suggests seeding of the airway 
resistome may occur, through aspiration of gut microbes, in the case of ermF and msrD, 
contrasting ermX which strongly associates more directly with the respiratory microbiota. 
Silent aspiration and/or gastroesophageal reflux is proposed to occur in chronic respiratory 
disease including asthma, COPD and bronchiectasis and therefore should be considered as a 
contributor to the airway resistome (43-46).
To better understand direct relationships and potential transfer between host and environmental 
resistomes, we next assessed metagenomes in paired patient-inhaler specimens in individual 
patients. We demonstrate that an inhaler swab, when subjected to metagenomics, may act as a 
surrogate of the airway microbiome and/or resistome: a feature of relevance in dry non-
productive patients commonly seen in severe asthma but also COPD and bronchiectasis (47). 
Co-occurrence of microbe-resistance gene combinations was evident, strongly indicative of 
environmental contributors and microbial sources of the airway resistome. By generating 
comparable microbiome and resistome profiles between airway and inhalers, we confirm the 
potential for such therapeutic devices to act as resistance reservoirs, allowing trafficking of 
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pathogenic microbes and resistance determinants between the environment and airway. Recent 
work illustrates the COPD airway to be an important reservoir for antibiotic resistance genes, 
linking their abundance to bacterial colonization (11). Interestingly, existing data further 
proposes that macrolide resistance genes, including ermX may be aerosolised and associate 
with COPD patient filter masks in the hospital setting (48). Our work further builds on such 
concepts demonstrating the potential of clinical metagenomics in inhaler devices to uncover 
microbe-resistance gene associations through gene-species co-occurrence in environmental 
and airway specimens. We identify a subset of microbes and genes co-occurring between the 
airway and inhaler surface when integrated into a co-occurrence network leading to the 
identification of bacteria highly correlated to genes conferring macrolide, tetracycline,  -
lactam and fluoroquinolone resistance. Interestingly, this reveals taxa previously associated 
with antimicrobial resistance including Actinomyces, Streptococcus and Prevotella species, 
implicating them as potential key vehicles for resistance (36, 49). Prevotella is known to 
exhibit reduced susceptibility to -lactams in the CF lung, findings consistent with our 
observed association between P. pallens and the -lactamase-encoding cfxA2 gene, while the 
presence of tet genes in Streptococcus is also previously described (50). Association between 
Carnobacterium maltaromaticum and msrD is not previously described although the clinical 
relevance of Carnobacterium species remains to be fully established. Our detected relationship 
between Actinomyces species and resistance genes appears in contradiction to its described 
macrolide sensitivity however it should be noted that molecular (sequence) data related to 
Actinomyces spp. ICM47 has yet to be taxonomically confirmed, and, therefore potentially 
represents an exception to the general trend in this genera favouring macrolide susceptibility 
(30). 
Our work is novel and represents the largest clinical metagenomics study performed on airway 
specimens using robust state-of-the-art methodologies effectively applied to low biomass 
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samples such as outdoor air (23). Using this approach, we uncover a core airway resistome 
dominated by macrolide resistance linked to the host microbiome. We further illustrate that 
inhaler devices may act as a surrogate of the host airway microbiome and remain a key 
resistance reservoir. Despite our study’s strengths and novelty, we acknowledge its limitations. 
First, despite being the largest clinical metagenomics study to date, we include only n=85 
individuals which are further nested into healthy and diseased groups, within a cross-sectional 
study design requiring validation in larger longitudinal studies given the myriad of confounders 
that could possibly influence microbiome profiles. For instance, while diseased patients were 
relatively well matched for age, the healthy cohort were significantly younger. Even with a 
limited sample size, we could identify microbiome perturbation characteristic of respiratory 
disease (e.g. COPD and bronchiectasis). Heterogeneity and relationships between the resistome, 
microbiome and specific disease phenotypes (e.g. very frequent exacerbators) within the 
diseased cohorts, most prominent for the bronchiectasis group, could not be fully resolved by 
this work because of the limited sample size. Recently, Taylor and colleagues have 
demonstrated the effect of macrolide exposure on the resistome in a longitudinal study of 
patients with severe asthma. Following azithromycin exposure, the abundance of several 
macrolide genes (including those observed in our analysis) ermB, ermF, mef and mel (msrD) 
were detected, supporting the functional importance of these genes to the resistome in response 
to antibiotic exposure (30). Interestingly, shifts in the resistome in response to therapy were 
accompanied by clinical resistance in H. influenzea isolates suggesting metagenomic resistome 
profiling may reflect clinically observed resistance that warrants further analysis in terms of 
diagnostic implications in the context of the findings from our study. Next, while metagenomic 
shotgun sequencing is a powerful tool, it remains relatively expensive with slower turnaround 
times compared to other sequencing approaches. This poses challenges for real-time diagnostic 
or therapeutic use and translation into everyday clinical practice (51). Though challenging due 
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to the nature of sample variability in particular conditions such as asthma or (dry) 
bronchiectasis compared to non-diseased controls, as a matrix, sputum is advantageous in terms 
of accessibility and scope for broad application in large studies across a range of clinical 
settings. This clearly contrasts with more invasive BAL or tissue biopsy sampling where 
sample acquisition and control subject recruitment are major limiting factors. Our study 
recruited several non-diseased participants from which airway specimens were readily obtained 
by applying the ‘huff cough’ technique in a protocol applied previously to non-diseased control 
samples in assessment of their airway microbiomes (21).  Though clearly important, the degree 
to which sputum reflects the true microbial ecosystem of the lower airway has been the subject 
of debate, and, its accessibility likely comes at a cost of reduced resolution of lower airway 
taxa which may be particularly relevant in diseased states (52). Consistency of sputum 
sampling in terms of the relative proportions of upper and lower airway biomass in a given 
sample, variability in sampling during acquisition and also changes with respect to disease 
severity are all likely to influence clinical association and remain important areas for future 
exploration. In our assessment of patient inhalers, we included rigorous swab-sampling 
contamination controls but lacked the additional experimental control of a swab taken from an 
unused inhaler device – an important consideration given the sensitivity of metagenomics to 
detect minute levels of background contamination. The high abundance of human DNA in 
sputum is an additional hurdle with implications for adequate and unbiased detection of 
resistance genes, as sequencing depth will influence detection. However, recent work in the 
area of host DNA removal may address this issue, allowing for greater microbial read depth 
and scalability of sputum metagenomics in this field (53). Furthermore, metagenomic data 
processing requires specialised personnel with bioinformatic skills and a facility with the 
capability to perform high-performance computing, both significant barriers to clinical 
implementation. The use of short read sequencing also largely precludes a definitive 
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assessment of mobile genetic elements associated with resistance genes and long-read 
metagenomic workflows currently being developed may offer better insights going forward. 
Finally, our study detected change to genes controlling lipid metabolism across a range of 
chronic respiratory disease states. Alterations in lipid metabolism are identified in COPD and 
bronchiectasis, and, potentially contribute to their pathogenesis through initiation and 
resolution of inflammation. Emerging data suggests that microbial dysbiosis associates with 
such metabolic change and remains an important avenue for future study particularly in regard 
to effect on host immune function (26, 54, 55).
Despite economic, analytical and resource related challenges to the application of clinical 
metagenomics into respiratory practice, its ability to concurrently capture individual microbial 
taxonomy, function and resistance in an unbiased robust manner using a single specimen makes 
it an attractive tool for the delivery of precision respiratory medicine. This is important in the 
current era of patient endo-phenotyping including disease overlap. Our identification of a core 
airway resistome, dominated by macrolide resistance, is an important cautionary warning 
worthy of clinical consideration. Despite advances in the use of antimicrobials to improve 
clinical outcomes across a range of chronic respiratory diseases, we must be cognisant of their 
potential long-term resistance implications and weigh this against the perceived short-term 
clinical benefit in individual respiratory patients.   
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FIGURE LEGENDS
Figure 1. Airway shotgun metagenomics reveals functional metabolic dysbiosis and an 
increased antibiotic resistance gene abundance across chronic respiratory disease states. (A) 
Heatmap illustrating the relative abundance of functionally classified sequence reads assigned 
to functional categories (KEGG) in each microbiome profile. Values are expressed as Z-scores 
(calculated based on the deviation from the mean abundance in each group and scaled to the 
standard deviation). Higher abundance (indicated in red) associated with specific functional 
pathways including lipid metabolism, xenobiotic biodegradation and antibiotic-associated 
biosynthetic pathways. These are highest in patients with COPD and bronchiectasis. (B) 
Heatmap illustrating specific antibiotic-resistance gene abundance (by class) based on read 
alignment to the CARD antibiotic resistance database. -lactam, fluoroquinolone, macrolide 
and tetracycline resistance genes are detectable in diseased and non-diseased subjects. Patients 
with COPD and bronchiectasis have the highest load of antibiotic resistance determinants. (C) 
Patient antibiotic usage and respective class (in the preceding six months preceding airway 
sampling) is indicated by black dots (). COPD: Chronic Obstructive Pulmonary Disease.
Figure 2. A core airway resistome exists across respiratory disease states including antibiotic-
naïve and non-diseased (healthy) individuals. (A) Venn diagram illustrating the number of 
individual antibiotic resistance genes among the study cohorts and their intersections; ND: 
Non-Diseased, SA: Severe Asthma, COPD: Chronic Obstructive Pulmonary Disease and BE: 
Bronchiectasis. (B) An Upset plot, corresponding to the presented Venn diagram (2A) 
illustrating the antibiotic resistance gene composition across individual cohorts and their 
intersections. Stacked bar charts reflect the detected antibiotic resistance genes coloured 
according to antibiotic class. Individual groups and their intersections are indicated for each 
cohort separately (ND; SA; COPD and BE) followed by their respective intersection by a 
matrix (located below stacked bars). Set size, i.e. the number of resistance genes detected per 
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group is indicated by horizontal bars (ND<SA<COPD<BE). Black dots () indicate sets and 
connecting lines indicate relevant intersections related to each stacked bar chart. An 18-gene 
‘core’ resistome was identified (across all four cohorts) and largely comprises of genes 
conferring macrolide, tetracycline, -lactam and aminoglycoside resistance, while the 32 genes 
shared by COPD and bronchiectasis patients are predominantly multi-drug and triclosan 
resistance classes. (C) Heatmap illustrating specific antibiotic resistance genes by class and 
individual cohort.  Specific antibiotic resistance genes grouped by coloured class (x-axis) are 
plotted against individual cohorts (ND; SA; COPD and BE) (y-axis). Genes are presented in 
order of detected abundance with msrD (mel), ErmB, ErmF, and ErmX macrolide resistance 
genes most frequently observed across all four cohorts followed by genes encoding tetracycline, 
-lactam and fluoroquinolone resistance.
Figure 3. Metagenomic microbiome taxonomic composition exhibits disease-associated 
signatures with greatest heterogeneity in COPD and bronchiectasis. (A) Bubble chart 
illustrating microbial abundance of discriminant taxa in non-diseased vs diseased cohorts based 
on species-level classification. Bubble size corresponds to read count and phylum membership 
is colour-coded. Rothia mucilaginosa was consistently increased in diseased versus non-
diseased subjects (Dunn’s test, p = 0.01) while Pseudomonas aeruginosa was also increased, 
most notably among bronchiectasis patients (Dunne test’s, p = 0.02) (B)  A non-metric multi-
dimensional scaling plot (NMDS) illustrating -diversity between the study groups including 
ND: Non-Diseased (dark blue), SA: Severe Asthma (light blue), COPD: Chronic Obstructive 
Pulmonary Disease (purple) and BE: Bronchiectasis (red), each highlighted by a coloured 
ellipse (C) The average distances to centroid from the NMDS plot was measured using the 
PERMDISP test of homogeneity and  plotted for each respective study group illustrating the 
heterogeneity of their respective microbiome profiles (error bars reflect standard deviation). 
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Difference in average distance to centroid was formally confirmed by ANOVA and Tukey 
post-hoc analysis; ***p <0.001.
Figure 4. Network inference through co-occurrence analysis reveals gene-microbe 
associations of the ‘core’ macrolide resistome.  (A) Antibiotic resistance genes within the co-
occurrence network are colour-coded with respect to antibiotic class while microbes are 
coloured black. Grey lines denote interactions between nodes (representing both microbes and 
resistance genes) with line thickness reflecting their observed interaction strength respectively. 
Interactions between resistance genes are highlighted by red lines. (B) Microbes within the co-
occurrence network are colour-coded with respect to their species while antibiotic resistance 
genes are coloured black. Grey lines denote interactions between nodes (microbes or resistance 
genes) with thickness reflecting interaction strength. Interactions between species are 
highlighted by red lines. (C-E) Identified nodes of the macrolide resistome are highlighted 
indicating the specific microbes (by species) that associate with (C) ermX, (D) ermF and (E) 
msrD. Line thickness reflects the observed interaction strength between microbial nodes and 
the central resistance gene while arrow heads depict directionality of the co-occurrence 
prediction.
Figure 5. Metagenomics assessment of inhaler devices as potential antibiotic resistance 
reservoirs. Metagenomics shotgun analyses was performed on paired (airway-inhaler) 
specimens obtained through sputum collection and swabbing of mouthpieces of patient inhaler 
devices (n=total 31 pairs consisting of n=16 (severe asthma); n=11 (COPD) and n=4 
(bronchiectasis). (A) Microbiome profiles of paired airway-inhaler devices exhibits a 
comparable overall pattern illustrated by stacked bar plots of a species-level relative abundance. 
(B) Venn diagram illustrating the observed metagenomics-derived microbial taxa present in 
the airway (green set, ‘A’, n = 116) and inhaler device (grey set, ‘I’, n = 207) and the co-
occurrence of microbial species that are detectable in both groups (intersect, n = 80). Thirty-
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six and 127 species were therefore unique to the airway sputum and inhaler metagenomics 
profiles respectively. (C) Horizontal bar plot indicating microbial species confirmed to co-
occur in paired specimens, i.e. species found in both the airway and inhaler device of the same 
patient (n = 63 species). (D) Resistance gene profiles for paired airway-inhaler devices 
demonstrate comparability with a higher abundance of resistance genes (measured in RPKM - 
Reads Per Kilobase Million) detected in airway specimens. (E) Venn diagram illustrating the 
observed diversity of resistance genes detected in airway specimens (green set, ‘A’, n = 89) 
and inhaler devices (grey set, ‘I’, n = 98) by metagenomics. Co-occurrence of a significant 
number of microbial species were detected (intersect, n = 53 species). Thirty-six and 45 
resistance genes were unique to the airway sputum and inhaler metagenomics profiles 
respectively. (F) Horizontal bar plot indicating resistance genes confirmed to co-occur in paired 
specimens, i.e. genes found in both the airway and inhaler device of the same patient (n = 46 
genes). Genes co-occurrences observed in n ≥ 2 subjects are plotted.
Figure 6. Metagenomic derivation of microbe-gene associations highlighting a potential 
source of resistance implicated in airway-inhaler device cross-over. (A) Correlation plot of 
microbes and resistance genes co-identified in metagenomic profiles from paired patient 
airway and inhaler device specimens. The presence of a circle indicates significant association 
(p<0.05) while circle size and colour intensity reflect observed Pearson’s correlation for all 
pairwise comparisons indicating the strong positive correlations detected between microbes 
and resistance genes. The antibiotic resistance genes are colour coded according to their 
respective antibiotic class (B) Bubble chart illustrating the co-occurrence of the most highly 
correlated microbe (empty circle) and resistance gene (filled circle) combinations illustrated 
by disease i.e. Severe Asthma (SA), COPD and bronchiectasis (BE). Bubble size represents 
the number of classified reads while colour indicates the antibiotic class. Black bars along x-
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axis indicate each individual paired airway and inhaler specimen respectively (from left to 
right).
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Table 1. Patient Demographics
Demographic Diseased (D) p-valueNon-diseased 
(ND)
Severe Asthma COPD Bronchiectasis ND vs D D v D
N 13 11 15 15
Age 34±8 70±17 70±9 64±15 <0.001 0.472
Gender 0.528 0.012
     Male 62% (8) 73% (8) 100% (15) 53% (8)
     Female 38% (5) 27% (3) 0% (0) 47% (7)
BMI 23±3 27.9±8 21.7±8 18.4±6 0.237 0.009
FEV1 predicted 109±14 72±14 45±13 65±20 <0.001 0.005
Disease severity †
     Mild - 0% (0) 7% (1) 6% (1) - 0.797
     Moderate - 27% (3) 40% (6) 27% (4)




0±0 0±1.5 3±3 2±1 0.032 0.013
Smoking status <0.001 <0.001
     Never smoker 100% (13) 91% (10) 0% (0) 67% (10)
     Ex-smoker 0% (0) 0% (0) 47% (7) 27% (4)
     Current smoker 0% (0) 9% (1) 53% (8) 7% (1)
Antibiotic use in 6 
months preceding 
recruitment 0.050 <0.001
     Yes 0% (0) 0% (0) 67% (10) 20% (3)
     No 100% (13) 100% (11) 33% (5) 80% (12)   
Inhaled 
corticosteroid use
Yes - 100% (11) 53% (8) 53% (8) - 0.064
No - 0% (0) 47% (7) 47% (7)
Inhaled 
bronchodilator use
Yes - 100% (11) 100% (15) 53% (8) - 0.009
No - 0% (0) 0% (0) 47% (7)
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† Defined according to disease-specific criteria. Severe asthma: ACT score;  20 = “mild”, 
19-15 = “moderate”, <15 = “severe”. COPD: GOLD stage; 1 = “mild”, 2 = “moderate”,  3 = 
“severe”. Bronchiectasis: Bronchiectasis Severity Index (BSI); 0-4 = “mild”, 5-8 = 
“moderate”,  9 = “severe”. 
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Table 2. Genes of the core ‘resistome’ (n =18) identified across study cohorts.
Gene name Drug class Resistance mechanism
aac(3)-VIIa aminoglycoside antibiotic inactivation
aph(3)-IIIa aminoglycoside antibiotic inactivation
oxa-255 cephalosporin, penam (β-lactam) antibiotic inactivation
cfxA2 cephamycin (β-lactam) antibiotic inactivation
dfrA1 diaminopyrimidine antibiotic target replacement
pmrA fluoroquinolone antibiotic efflux
mel (msrD) macrolide, lincosamide, streptogramin, tetracycline, 
phenicol, oxazolidinone, pleuromutilin
antibiotic target protection
ermB macrolide, lincosamide, streptogramin antibiotic target alteration
ermF macrolide, lincosamide, streptogramin antibiotic target alteration
ermX macrolide, lincosamide, streptogramin antibiotic target alteration
lnuC lincosamide antibiotic inactivation
efrB rifamycin, macrolide, fluoroquinolone antibiotic efflux
catS phenicol antibiotic inactivation
tetA(46) tetracycline antibiotic efflux
tetW tetracycline antibiotic target protection
tetB(46) tetracycline antibiotic efflux
tet(D) tetracycline antibiotic efflux
tetO tetracycline antibiotic target protection
Page 37 of 61
 AJRCCM Articles in Press. Published April 22, 2020 as 10.1164/rccm.201911-2202OC 
 Copyright © 2020 by the American Thoracic Society 
Figure 1
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Figure 2 (a-b)
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Figure 2 (c)
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Figure 3 (a)
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Figure 3 (b-c)
Page 42 of 61
 AJRCCM Articles in Press. Published April 22, 2020 as 10.1164/rccm.201911-2202OC 



























































Page 43 of 61
 AJRCCM Articles in Press. Published April 22, 2020 as 10.1164/rccm.201911-2202OC 


























Page 44 of 61
 AJRCCM Articles in Press. Published April 22, 2020 as 10.1164/rccm.201911-2202OC 




















































































36         80             127



































































































Page 45 of 61
 AJRCCM Articles in Press. Published April 22, 2020 as 10.1164/rccm.201911-2202OC 











































































































































































































































































































































































































































Page 46 of 61
 AJRCCM Articles in Press. Published April 22, 2020 as 10.1164/rccm.201911-2202OC 

























































































Page 47 of 61
 AJRCCM Articles in Press. Published April 22, 2020 as 10.1164/rccm.201911-2202OC 
 Copyright © 2020 by the American Thoracic Society 
Online Data Supplement
Metagenomics Reveals a Core Macrolide Resistome Related to Microbiota in Chronic 
Respiratory Disease
Micheál Mac Aogáin, Kenny J. X. Lau, Zhao Cai, Jayanth Kumar Narayana, 
Rikky W. Purbojati, Daniela I. Drautz-Moses, Nicolas E. Gaultier, Tavleen K. Jaggi, 
Pei Yee Tiew, Thun How Ong, Mariko Siyue Koh, Albert Lim Yick Hou, 
John A. Abisheganaden, Krasimira Tsaneva-Atanasova, 
Stephan C. Schuster and Sanjay H. Chotirmall.
*These authors contributed equally
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SUPPLEMENTARY MATERIALS AND METHODS
Ethical approval: This study was approved by the institutional review boards of all 
participating sites as follows and all included participants provided written informed consent: 
CIRB 2016/2628 (severe asthma), CIRB 2016/2715, CIRB 2016/2549 (COPD), CIRB 
2016/2073 (bronchiectasis) (all mutually recognised by DSRB) and NTU IRB-2016-01-031 
and IRB-2017-12-010 (healthy individuals and diseased patients).
DNA extraction and sequencing
Spontaneously expectorated and representative sputum was obtained from all study 
participants according to established, standardised and published collection and assessment 
protocols (1, 2). DNA was extracted from representative sputum using the Roche High-pure 
PCR Template Preparation Kit (Roche) as previously described (3-5). To assess the 
environmental metagenome present on the mouthpieces of patient inhalers, 4N6Floq swabs 
(Copan, USA) pre-moistened in phosphate buffered saline (PBS) with 0.1% Triton-X100 
(Sigma-Aldrich, USA) were used and the inhaler used most frequently sampled. After sampling, 
the swabs were snapped into a DNeasy PowerWater kit (Qiagen, Germany) bead tube. DNA 
was extracted and processed according to the manufacturer’s protocol with the addition of 
proteinase K (Sigma-Aldrich, USA) and sonication at 65ºC (6). Sterile swabs and reagents 
were processed simultaneously as extraction controls to assess the levels of background 
contamination and subjected to metagenomic analysis which confirmed lower-level 
background contamination in sputum (11428-59428 reads, n =4) and swab (1175-4487 reads, 
n =6) extraction controls (Supplementary Figure E2). Extracted DNA was quantitated using 
the Qubit dsDNA High Sensitivity (HS) Assay Kit (Invitrogen, USA) and sequenced on a 
HiSeq 2500 platform (Illumina, USA) according to library preparation and DNA sequencing 
methods described by Gusareva, et al. (7).  All sequence data from this study has been uploaded 
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to the National Center for Biotechnology Information (NCBI) Sequence read archives (SRA) 
under project accession PRJNA595703.
Functional and taxonomic assignment of metagenomic sequence reads
Raw sequencing reads with a minimum Phred score 20 and >30 bp in length were selected and 
adapter-trimmed using Cutadapt (version 1.14) (8). Trimmed reads were then mapped against 
the GRCh38 human reference genome with bowtie2 (version 2.3.2) (9). Unmapped non-host 
reads were separated for further analysis and aligned against the NCBI non-redundant protein 
database (7 August 2017) with Diamond (version 0.9.9) (10). Based on these alignments, 
microbial taxonomical classification was generated using the Lowest Common Ancestor (LCA) 
algorithm implemented in MetaGenome Analyzer (MEGAN, v6.8.18) with a minimum score 
of 100 and a support of ≥25 (11). Functional annotation according to the Kyoto Encyclopedia 
of Genes and Genomes (KEGG) was performed in MEGAN based on the ‘acc2kegg-Dec2017’ 
database visualizing metabolism-associated functions. Resistance genes present among non-
host reads were identified using ShortBRED (12). Unique protein markers were created by 
applying the ‘shortbred_identify.py’ script with a 95% cluster identity using antimicrobial 
resistance (AMR) protein sequences from Comprehensive Antibiotic Resistance Database 
(CARD) and Uniref90 database as a reference (13, 14). The abundance of unique protein 
markers was determined using the shortbred_quantify.py script based on average read length 
of 200 bp. Drug class assignments were manually validated against the CARD database. 
Normalized gene abundances were expressed in reads per kilobase million mapped reads 
(RPKM) relative to each AMR gene.
Data analysis, visualisation and statistical analysis
All continuous data was tested for normality by the Kolmogorov-Smirnoff test. Categorical 
data was assessed by Chi-squared or Fisher’s exact test as appropriate. For non-normal data, 
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Mann-Whitney U-testing was used for group comparisons. For comparison of three or more 
groups of non-normal measures, the Kruskal-Wallis test was employed with Dunn’s post hoc 
test and Benjamini-Hochberg correction for multiple comparisons. Differences were 
considered significant at p <0.05. 
Read functional assignments were visualised using heatmaps with abundance coloured 
according to Z-scores in MEGAN while the RPKM values of AMR genes were plotted using 
the ‘heatmap.2’ function from the R package ‘gplots’ (15). A list of AMR genes was extracted 
and plotted in a Venn diagram using both the ‘venndiagram’ and ‘upsetR’ packages to examine 
the similarities in AMR profiles across healthy and diseased groups (16, 17). Principal 
coordinate analysis (PCoA) plots of taxonomic data were generated using ‘vegan’ and 
‘phyloseq’ packages to observe clustering patterns among the four studied groups (18, 19). The 
average distance to centroid of each group was determined using PERMDISP tests of 
homogeneity of dispersions by the ‘betadisper’ function in ‘vegan’. The significance of 
distances to centroid differences obtained between groups was assessed by analysis of variance 
(ANOVA) with Tukey’s post hoc analysis. Linear discriminant analysis between cohorts was 
performed with lefse (version 1.0) with default parameters (20). Assigned reads were visualised 
in MEGAN as bubble charts representing normalised read counts. Co-occurrence networks 
were generated by combining normalised AMR and taxonomic data and assessed several 
network metrics using generalized boosted linear models (GBLMs) as described by Faust et 
al. (21). Pearson’s correlation for co-occurring taxa and resistance genes were visualised in R 
using the ‘rcorr’ function from the ‘Hmisc’ package, with consideration of correlation strength 
and significance (p > 0.05)  (22). 
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SUPPLEMENTARY FIGURE LEGEND
Supplementary Figure E1. Bar plot of metagenomic read assignments across cohorts. The 
abundance of non-human reads assigned to bacterial (purple), fungal (red) and viral taxa 
(yellow) is illustrated. Dark and light grey coloration denotes non-human reads with non-
deterministic or no hits in the reference database. 
Supplementary Figure E2. Metagenomic sequence analysis of control samples to assess 
background DNA contamination profiles of DNA extraction blanks. Four negative ‘blank’ 
DNA extractions, using only PBS and following our sputum extraction protocol (“sputum”) 
and six DNA extractions from sterile swabs following our swab extraction protocol (“Swab”) 
were performed and subjected to metagenomic sequencing. Assigned taxonomy for the most 
abundant species is colour-indicated in the legend provided within the figure. 
Supplementary Figure E3. Box and whisker plots illustrating the -diversity of the 
respiratory microbiome in Non-diseased (ND), Severe asthma (SA), Chronic obstructive 
pulmonary disease (COPD) and bronchiectasis (BE) patients included in this study. Plots 
indicating calculated (A) Shannon, (B) Simpson and (C) Chao1diversity indices for each group 
are analysed by ANOVA with Tukey post-hoc analysis; *p<0.05, **p<0.01 (D) Identification 
of discriminant taxa based on linear discriminant analysis (LDA) effect size (LEfSe). The 
observed effect sizes of discriminant taxa identified among diseased patients (‘D’) are indicated 
by the upper right-facing bars while those discriminant for non-diseased subjects (‘ND’) are 
indicated by lower left-facing bars. Colour represents phylum membership. (E) Bubble chart 
summarizing the taxonomic profiles of all four study groups, classified to genus level. Bubble 
size reflects read abundance and colour indicates phylum-level association. 
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SUPPLEMENTARY TABLES
Supplementary Table E1: Demographics for paired patient-inhaler metagenomes 
Demographic Disease
Severe Asthma COPD Bronchiectasis
N 16 11 4
Age 64±19 68±5 65+11
Gender
     Male 19% (3) 100% (11) 25% (1)
     Female 81% (13) 0% (0) 75% (3)
BMI 24.7±9 22.3±3 19.4±5
FEV1 % predicted 78±18 58±33 66±14
Disease severity †
     Mild 32% (5) 0% (0) 50% (2)
     Moderate 32% (5) 55% (6) 0% (0)
     Severe 36% (6) 45% (5) 50% (2)
Exacerbations in year 
preceding study 
recruitment 2±5 0±0.3 2±0.1
Smoking status
     Never smoker 75% (12) 0% (0) 75% (3)
     Ex-smoker 19% (3) 55% (6) 25% (1)
     Current smoker 6% (1) 45% (5) 0% (0)
Antibiotic use in 6 months 
preceding recruitment
     Yes 0% (0) 0% (0) 0% (0)
     No
100% (16) 100% (11) 100% (4)
Inhaled corticosteroid use
Yes 100% (16) 36% (4) 25% (1)
No 0% (0) 64% (7) 75% (3)
Inhaled Bronchodilator use
Yes 100% (16) 100% (11) 75% (3)
No 0% (0) 0% (0) 25% (1)
† Defined according to disease-specific criteria. Severe asthma: ACT score;  20 = “mild”, 19-
15 = “moderate”, <15 = “severe”. COPD: GOLD stage; 1 = “mild”, 2 = “moderate”,  3 = 
“severe”. Bronchiectasis: Bronchiectasis Severity Index (BSI); 0-4 = “mild”, 5-8 = “moderate”, 
 9 = “severe”. 
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Supplementary Table E2: Putative environmental resistance genes found in association with 
inhaler devices but absent in sputum. 
Gene name Drug class Resistance mechanisms 
aac(3)-VIIa aminoglycoside antibiotic inactivation
aph(3'')-Ib aminoglycoside antibiotic inactivation
BUT-1 cephalosporin (β-lactam) antibiotic inactivation
qacA fluoroquinolone antibiotic efflux
lfrA fluoroquinolone antibiotic efflux
lnuA lincosamide antibiotic inactivation
mgrA antibiotic peptide, fluoroquinolone, tetracycline, penam, 
cephalosporin, acridine dye
antibiotic efflux
vgaALC streptogramin, pleuromutilin, oxazolidinone, macrolide, 
tetracycline, lincosamide, phenicol
antibiotic target protection
msrA streptogramin, pleuromutilin, oxazolidinone, macrolide, 
tetracycline, lincosamide, phenicol
antibiotic target protection
sdiA tetracycline, penam, phenicol, rifamycin, cephalosporin, 
glycylcycline, triclosan, fluoroquinolone
antibiotic efflux
cmx phenicol antibiotic efflux
tet(38) tetracycline antibiotic efflux
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Supplementary Figure E3 (a-d)
A. B. C. D.
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Supplementary Figure E3 (e)
E.
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